Shufeng Weng, Jinyi Zhang, Huixia Ma, Jingyu Zhou, Liqiu Jia, Yanmin Wan, Peng Cui, Qiaoling Ruan, Lingyun Shao, Jing Wu, Honghai Wang, Wenhong Zhang, Ying Xu
Latent tuberculosis infection (LTBI) treatment is known to accelerate the decline in TB incidence, especially in high-risk populations. Mycobacterium tuberculosis ( M. tb ) expression profiles differ at different growth periods, and vaccines protective and therapeutic effects may increase when they include antigenic compositions from different periods. To develop a post-exposure vaccine that targets LTBI, we constructed four therapeutic DNA vaccines ( A39 , B37 , B31 , and B21 ) using different combinations of antigens from the proliferation phase (Ag85A, Ag85B), PE/PPE family (Rv3425), and latent phase (Rv2029c, Rv1813c, Rv1738)...
2022: Frontiers in Immunology